Fiztasovimab
Based on 1 Customer Validation
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
For research use only. We do not sell to patients.
- Purity : 96.49%
- CAS No.: 2467411-25-0
- Molecular Weight:144.49 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-N1127
TricinCMV Inhibitor -
HY-16305
MaribavirAnti-CMV Agent -
HY-15523
Braco-19Telomerase Inhibitor -
HY-109528
Fomivirsen sodiumCMV Inhibitor -
HY-A0032A
Valganciclovir hydrochlorideAntiviral Agent -
HY-15523A
Braco-19 trihydrochlorideTelomerase Inhibitor -
HY-16305R
Maribavir (Standard)Anti-CMV Agent -
HY-108261
TomeglovirCMV Inhibitor -
HY-100272
B220Antiviral Agent -
HY-A0032AR
Valganciclovir hydrochloride (Standard)Antiviral Agent -
HY-N1127R
Tricin (Standard)CMV Inhibitor
Biological Activity
Description
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
HCMV
In Vitro
Fiztasovimab is isolated from Epstein-Barr virus-transformed peripheral B cells of a healthy donor[1].
Fiztasovimab has a broadly neutralizing activity against 4 laboratory strains (AD169, Towne, Davis, Merlin) and 42 Japanese clinical isolates, which included GCV-resistant isolates[1].
Fiztasovimab shows anti-hMCV activities in MRC-5 human embryonic fibroblast cells and human adult retinal pigment epithelial cells with IC50s of 13-105 ng/mL and IC90s of 0.208-1.026 μg/mL[1].
Fiztasovimab also inhibits cell-to-cell infection by hCMV isolates in adult retinal pigment epithelial cells with IC90s of 13-19 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
3077416 [NCBI]
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human cytomegalovirus (HCMV) Glycoprotein B/gB Protein can bind Fiztasovimab. The EC50 for this effect is 20.15 ng/mL.
Chemical Information
-
CAS No. 2467411-25-0
-
Appearance Liquid
-
Molecular Weight 144.49 kDa
-
Color Colorless to light yellow
-
SMILES
[Fiztasovimab]
-
Synonyms
NPC-21; EV2038
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell neural induction and neuron differentiation
Human pluripotent stem cell neural induction can be achieved by blocking BMP and TGFβ/Activin/Nodal SMAD signaling, which suppresses non-neural differentiation and promotes early neuroectodermal identity; the expected readout is loss of pluripotency markers such as OCT4 and induction of neural markers such as PAX6, followed by neural progenitor and neuron marker acquisition during differentiation. This protocol uses dual-SMAD neural induction as the core induction method, followed by cortical neuron differentiation as a representative neuron differentiation model; published cortical protocols describe generation of cortical progenitors, temporally ordered cortical projection neurons, action-potential firing, synaptogenesis, and neural network formation over an approximately 80-day process.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fiztasovimab Related Classifications
HY-P99621 Related Classifications
Powered by Bioz